Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

Ovarian Cancer Screening References

  1. Ries LAG, Harkins D, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD.

  2. Brinton, LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril. 2004; 82:405-14. [PubMed Abstract]

  3. Rossing MA,Tang MC, Flagg EW, Weiss LK. Wicklund KG. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol. 2004 Dec 1;160(11):1070-8. [PubMed Abstract]

  4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288:321-33. [PubMed Abstract]

  5. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol. 2002; 155:217-24. [PubMed Abstract]

  6. Gertig DM, Hunter DJ, Cramer DW, et al. Prospective study of talc use and ovarian cancer. J Natl Cancer Inst. 2000; 92:249-52. [PubMed Abstract]

  7. Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol Cancer. 2001; 11:423-9. [PubMed Abstract]

  8. Kjaer SK, Mellemkjaer L, Brinton LA, Johansen C, Gridley G, Olsen JH. Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65,000 sterilized women. Int J Epidemiol. 2004; 33:596-602. [PubMed Abstract]

  9. Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2 and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998; 178: 670-677. [PubMed Abstract]

  10. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68: 700-710. [PubMed Abstract]

  11. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104:2807-16. [PubMed Abstract]

  12. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997; 336:1401-8. [PubMed Abstract]

  13. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62:676-89. [PubMed Abstract]

  14. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72:1117-30. [PubMed Abstract]

  15. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997; 6:105-10. [PubMed Abstract]

  16. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999; 81:214-8. [PubMed Abstract]

  17. Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol. 1992; 80:700-7. [PubMed Abstract]

  18. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol. 1998; 105:493-9. [PubMed Abstract]

  19. Bergfeldt K, Rydh B, Granath F, et al. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet. 2002; 360:891-4. [PubMed Abstract]

  20. Kauff ND, Mitra M, Robson ME, et al. Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Negative Hereditary Breast Cancer Families. Journal of the National Cancer Institute. 2005; 97:1382-4. [PubMed Abstract]

  21. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999; 353:1207-10. [PubMed Abstract]

  22. Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. Health Technology Assessment. 1998; 2:1-84. [PubMed Abstract]

  23. van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000; 77:350-6. [PubMed Abstract]

  24. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005; 193:1630-9. [PubMed Abstract]

  25. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359:572-7. [PubMed Abstract]

  26. American Cancer Society. Ovarian Cancer: Can Ovarian Cancer Be Found Early? Atlanta, GA: American Cancer Society 2006.

  27. American College of Obstetricians and Gynecologists. ACOG Committee Opinion: The role of the generalist obstetrician in the early detection of ovarian cancer. Obstet Gynecol 2002; 100:1413-6. [PubMed Abstract]

  28. US Preventive Services Task Force. Screening for ovarian cancer: recommendation statement. Ann Fam Med. 2004; 2:260-2. [PubMed Abstract]

  29. National Cancer Institute. Ovarian Cancer (PDQ®): Prevention Health Professional Version. Bethesda, MD: National Cancer Institute, 2006.

  30. The National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. Clinical Practice Guidelines in Oncology. Version 1. 2006. [PubMed Abstract]